PTO/SB/08a (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
spond to a collection of information unless it contains a valid OMB control number.

5058-108 US

Under the Paperwork Reduction Act of 1995, 10 Complete if Known Substitute for form 1449A/PTO FEB 0 7 2008 Application Number 10/581,401 INFORMATION DISCLOSURE Filing Date June 1, 2006 STATEMENT BY A First Named Inventor Jean-Christophe PAGES 1633 TANK Art I Init (Use as many sheets as necessary) Examiner Name TED Marvich

Atlomey Docket Number

of

1

Sheet

Examiner

language Translation is attached.

/Maria Marvich/

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.1	Document Number Number-Kind Code 2 07 known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			

FOREIGN PATENT DOCUMENTS							
Examiner Initials	Cite No.1	Foreign Patent Document		Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant	Т
		Country Code 3 Number ⁴	Kind Code ⁶ (if known)	MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear	T ⁶
/M.M./		WO 98/13511 AI		04-02-1998	GOVERNMENT OF U.S.A.		Т
/M.M./		WO 03/072771 A2		09-04-2003	WAHLFORS et al.		
_							+-
							+

EXAMINER: Initial if reference considered, whether or not clation is in conformance with MPEP 809. Draw like through clation if not in conformance and not considered. Include copy of his form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.septo.gov or MPEP 901-00.1 - Effect Office that issued the document, by the two-before code (WIPO State) of ST3. - For Japanese patient document, his includation of the year of the reign of the Emporor must proceed the serial number of the patient document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Stated ST3. If 1902 is to place a better there if English

Date

Considered

03/26/2009

This collection of information is required by 37 CFR 197 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (appended by 50 LSC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete. Including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete the form and/or supagestines for reducing this burden, should be sent to the CFR the side of the complete complete the complete of the form and/or supagestines for reducing this burden, should be sent to the CFR the side of the comments on the complete to complete the side man darks supagestines for reducing this burden, should be sent to the CFR the side of the commence, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

FEB 0 7 7008

PTO/SB/08b (04-07

Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
s are required to respond to a collection of information unless it contains a valid OMB control number Under the Paperwork Red n Act of 1995, no pe

Substitute for form 14498 Complete if Known Application Number 10/581,401 INFORMATION DISCLOSURE Filing Date June 1, 2006 STATEMENT BY APPLICANT First Named Inventor Jean-Christophe PAGES Art Unit TBD (Use as many sheets as necessary) Examiner Name TBD Sheet of Attomey Docket Number 5058-108 US

xaminer itials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, senial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/M.M.	ń.	ROLLS, M.M. et al., "Novel Infectious Particles Generated by Expression of the Vesicular Stomatitis Virus Glycoprotein from a Self-Replicating RNA", Cell, November 4, 1994, pgs. 497-506, vol. 79, Cell Press	
	2.	ROLLS, M.M. et al., "Expression of Additional Genes in a Vector Derived from a Minimal RNA Virus", Virology, (1996), pgs. 406-411, no. 0211, Academic Press, Inc.	Ī
T	3.	LEBEDEVA, I. et al., "Infectious Particles Derived from Semiliki Forest Virus Vectors Encoding Murine Leukemia Virus Envelopes", Journal of Virology, Sept. 1997, pgs. 7061-7067, vol. 71, no. 9, American Society for Microbiology	T
	4.	RUSSELL, S.J. et al., "Modifying the Host Range Properties of Retroviral Vectors", The Journal of Gene Medicine, 499, pgs. 300-311, vol. 1, John Wiley & Sons, Ltd. 1999	
T	5.	SALONEN, A. et al., "Properly Folded Nonstructural Polyprotein Directs the Semiliki Forest Virus Replication Complex to the Endosomal Compartment", Journal of Virology, February 2003, pgs. 1691-1702, vol. 77, no. 3, American Society On Microbiology.	Ī
	6.	NALDINI, L. et al., "In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector", Science, April 12, 1996, pgs. 263-267, vol. 272	
	7.	IIU, M.L. et al., "Peaudornaeduction of Hepatocytes by Using Concentrated Beaudopped Vesicular Stomatitis Virus G diveoprotein (VSV-G)-Moloney Murina Leukenia Virus-Devived Retrovirus Vectors: Comparison of VSV-G and Amphotropic Vectors for Hepatic Gene Transfer", Journal of Virology, April 1996, pgs. 2497-2505, vol. 70, no. 4, American Society for Microbiology	l
	8.	LUNDSTROM, K. et al., "Novel Semiliki Forest Virus Vectors with Reduced Cytotoxicity and Temperature Sensitivity for Long-Term Enhancement of Transgene Expression", Molecular Therapy, February 2003, pgs. 202-209, vol. 7, no. 2, The American Society of Gene Therapy	
$\sqrt{}$	9.	MURIAUX, D. et al., "RNA is a Structural Element in Retrovirus Particles", Proc. Natl. Acad. Science, April 24, 2001, pgs. 5246-5251, vol. 98, no. 9	Ī
/M.M./	10.	Li, K.J. et al., "Packaging of Intron-Containing Genes into Retrovirus Vectors by Alphavirus Vectors", Cell Biology, March 1998, pgs. 3650-3654, vol. 95, Proc. Natl. Acad. Science, USA	T

Examiner	/Maria Marvich/	Date Considered	04/05/2009
Signature		Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include cpoy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTC/SB/08b (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Papervoik Reduction Red 0 165000 percent are required to respond to a collection of intermists under time to U.S. retain and incomment under the Comment as valid ONE control number

Substitute for form 144 PTO

INFORMATION THE CLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

(Use as many sheets as necessary)

Attorney Docket Number 5058-108 US

Sheet

of

Examiner nitials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2
M.M./	11.	WAHLFORS, J.J. et al., "Semiliki Forest Virus-Mediated Production of Retroviral Vector RNA in Retroviral Packaging Cells", Human Gene Therapy, November 20, 1997, pgs. 2031-2041, vol. 8, Mary Ann Liebert, Inc.	
/M.M./	12.	LUNDSTROM, K., "Alphavirus Vectors as Tools in Cancer Gene Therapp", Technology in Cancer Research & Treatment, February 2002, pgs. 83-88, vol. 1, no. 1, Adenine Press	Ī
/M.M./	13.	Dept. of Molecular Pharmacology, Standford University, Medical Center - Retroviral Systems Nolan Lab, website reference, http://www.standford.cdu/group/nolan/retroviral_systems/retsys.html,pgs. 1-2 downloaded 12/17/07	
			T
			T
			İ
			t

Examiner	/Maria Marvich/	Date	04/05/2009	
Signature	/Iviaria iviarvich/	Considered	04/03/2003	,

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include cpoy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by

In the USPTO to process an application. Confidentiality is governed by 38 USE, 128 and 37 EVR. 1.41. This collection is estimated to itself to the use of the USPTO. The results a benefit by the public which is to file age, becomed by 38 USE, C. 122 and 37 CFR. 1.14. This collection is estimated to its less 2 hours to complete, including entry, preparing, and submitting the completed application from the USPTO. Then will vary depending upon the individual case. Any comments to the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to should be sent to find information. Officer, U.S. Patent and Tolking U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DNT SEND FEES OR. COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA.22313-1450. DNT SEND FEES OR.